Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Assets (2016 - 2025)

Assembly Biosciences has reported Assets over the past 11 years, most recently at $257.6 million for Q4 2025.

  • Quarterly results put Assets at $257.6 million for Q4 2025, up 116.16% from a year ago — trailing twelve months through Dec 2025 was $257.6 million (up 116.16% YoY), and the annual figure for FY2025 was $257.6 million, up 116.16%.
  • Assets for Q4 2025 was $257.6 million at Assembly Biosciences, up from $240.0 million in the prior quarter.
  • Over the last five years, Assets for ASMB hit a ceiling of $278.9 million in Q1 2021 and a floor of $51.6 million in Q3 2023.
  • Median Assets over the past 5 years was $120.7 million (2022), compared with a mean of $149.0 million.
  • Biggest five-year swings in Assets: plummeted 57.51% in 2023 and later surged 139.37% in 2025.
  • Assembly Biosciences' Assets stood at $191.1 million in 2021, then plummeted by 46.72% to $101.8 million in 2022, then skyrocketed by 34.41% to $136.8 million in 2023, then fell by 12.9% to $119.2 million in 2024, then skyrocketed by 116.16% to $257.6 million in 2025.
  • The last three reported values for Assets were $257.6 million (Q4 2025), $240.0 million (Q3 2025), and $80.8 million (Q2 2025) per Business Quant data.